Barclays analyst Emily Field raised the firm’s price target on Eli Lilly (LLY) to $1,400 from $1,350 and keeps an Overweight rating on the shares. The firm increased estimates following the company’s Q1 report. Lilly’s “strong tirzepatide momentum takes focus back to the big picture,” the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly tells RBC liver case ‘not reasonably related to Foundayo’
- Eli Lilly fears for Foundayo ‘unfounded,’ says Wolfe Research
- Eli Lilly falls after FDA reports death of patient taking Foundayo
- Evercore says report in FAERS has ‘potential to create confusion’ for Eli Lilly
- The Week That Was, The Week Ahead: Macro and Markets, May 3